Switch to:

CRISPR Therapeutics AG Financial Strength

: 7 (As of Jun. 2020)
View and export this data going back to 2016. Start your Free Trial

CRISPR Therapeutics AG has the Financial Strength Rank of 7. It shows strong financial strength and is unlikely to fall into distressed situations.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate CRISPR Therapeutics AG's interest coverage with the available data. CRISPR Therapeutics AG's debt to revenue ratio for the quarter that ended in Jun. 2020 was 1,141.43. As of today, CRISPR Therapeutics AG's Altman Z-Score is 29.57.


Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


CRISPR Therapeutics AG Financial Strength Distribution

* The bar in red indicates where CRISPR Therapeutics AG's Financial Strength falls into.



CRISPR Therapeutics AG Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

CRISPR Therapeutics AG's Interest Expense for the months ended in Jun. 2020 was $0.0 Mil. Its Operating Income for the months ended in Jun. 2020 was $-80.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $40.3 Mil.

CRISPR Therapeutics AG's Interest Coverage for the quarter that ended in Jun. 2020 is

GuruFocus does not calculate CRISPR Therapeutics AG's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. CRISPR Therapeutics AG has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

CRISPR Therapeutics AG's Debt to Revenue Ratio for the quarter that ended in Jun. 2020 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2020 ) / Revenue (Q: Jun. 2020 )
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(9.906 + 40.317) / 0.044
=1,141.43

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

CRISPR Therapeutics AG has a Z-score of 29.57, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 29.57 is strong.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


CRISPR Therapeutics AG  (NAS:CRSP) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

CRISPR Therapeutics AG has the Financial Strength Rank of 7. It shows strong financial strength and is unlikely to fall into distressed situations.


CRISPR Therapeutics AG Financial Strength Related Terms


CRISPR Therapeutics AG Financial Strength Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)